The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.

OBJECTIVES: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen. METHODS: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML, (including AML patients with treatment-related and ELN-adverse risk disease (n = 50)). These patients were treated with venetoclax and hypomethylating agents and HAG regimens, respectively. RESULTS: Twenty-nine patients newly diagnosed with acute myeloid leukemia were treated with VEN-HMA (venetoclax-hypomethylating agent), while 23 patients were treated with HAG. The median age of the VEN-HMA group was 70 years, while the HAG group had a median age of 69 years. The VEN-HMA group achieved a significantly higher rate of complete remission (82.7%) compared to the cohort treated with the HAG regimen (21.7%) (P < 0.001). At the same time, the VEN-HMA group exhibited a significant survival advantage compared to the HAG treatment group(HR = 0.328, 95%CI: 0.158-0.683, P = 0.003).In patients with relapsed and refractory acute myeloid leukaemia, 43.8% of patients in the VEN-HMA treatment group achieved complete remission, which was similar to the 50% in the HAG treatment group (P > 0.99). The median overall survival was similar between the VEN-HMA and HAG groups, with 4 and 3.67 months, respectively (P = 0.290). CONCLUSIONS: In conclusion, our analyses indicated that VEN-HMA resulted in better therapeutic outcomes compared to HAG for newly diagnosed AML patients, with higher rates of complete remission and overall survival. In relapsed/refractory AML patients, there was no significant difference in the efficacy of the two treatments and further studies with larger sample sizes are warranted.

IL-33/ST2 axis promotes glioblastoma cell invasion by accumulating tenascin-C.

Tenascin-C (TNC), a very large multimeric glycoprotein, is overexpressed in human glioblastomas, leading to a highly motile and invasive phenotype of glioma cells. However, the regulation of TNC expression in glioma has remained unclear until now. Our data suggest that interleukin-33 (IL-33) may promote the accumulation of TNC protein by autocrine or paracrine modes of action in glioma. In the present study, the expression levels of TNC, IL-33, and ST2 were measured in glioma tissue specimens, and the impact of altered IL-33 expression on TNC was investigated in vitro and in vivo. In contrast with control treatment, IL-33 treatment increased TNC expression, and knockdown of IL-33 attenuated TNC expression in glioma cells. Furthermore, IL-33 induced the activation of nuclear factor κB (NF-κB) and increased the expression of TNC in U251 cells. In addition, blockage of the IL-33-ST2-NFκB pathway resulted in downregulation of TNC production. IL-33 promoted glioma cell invasion by stimulating the secretion of TNC. Similarly, knockdown of TNC inhibited the invasiveness of glioma cells. These findings provide a novel perspective on the role of the IL-33/NF-κB/TNC signalling pathway in supporting cancer progression. Thus, targeting the IL-33/NF-κB/TNC signalling pathway may be a useful therapeutic approach in glioma.

Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR.

[This corrects the article DOI: 10.3389/fphar.2018.01016.].

Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR.

Recent studies indicate that uPAR acts a crucial part in cell migration and the modulation of bone homeostasis. As a natural serine protease inhibitor, ulinastatin owns the capacity to reduce proinflammatory factors, downregulate the activation of NF-κB and mitogen-activated protein kinases (MAPKs) signaling pathways. Osteoclastogenesis has been demonstrated to be related with low-grade inflammation which involves cell migration, thus we speculate that ulinastatin may have a certain kind of impact on uPAR so as to be a potential inhibiting agent of osteoclastogenesis. In this research, we investigated the role which ulinastatin plays in RANKL-induced osteoclastogenesis both in vivo and in vitro. Ulinastatin inhibited osteoclast formation and bone resorption in a dose-dependent manner in primary bone marrow-derived macrophages (BMMs), and knockdown of uPAR could completely repress the formation of osteoclasts. At the molecular level, ulinastatin suppressed RANKL-induced activation of cathepsin K, TRAP, nuclear factor-κB (NF-κB) and MAPKs, and decreased the expression of uPAR. At the meantime, ulinastatin also decreased the expression of osteoclast marker genes, including cathepsin K, TRAP, RANK, and NFATc1. Besides, ulinastatin prevented bone loss in ovariectomized C57 mice by inhibiting the formation of osteoclasts. To sum up, this research confirmed that ulinastatin has the ability to inhibit osteoclastogenesis and prevent bone loss, and uPAR plays a crucial role in that process. Therefore, ulinastatin could be chosen as an effective alternative therapeutics for osteoclast-related diseases.

[Inducing-apoptosis effect of brucine on human monocytic leukemia cell line THP-1 and its mechanism].

This study was aimed to investigate the inducing-apoptosis effect of brucine on human monocytic leukemia cell line THP-1 cells and its possible mechanism. The inhibition effect of brucine on growth of THP-1 cells was measured by CCK-8 method. Morphological changes of THP-1 cells treated with brucine was detected by acridine orange/ethidium bromide (AO/EB)double staining. Annexin-V/PI double labeling method was used to assay the apoptosis rate of THP-1 cells. The effect of brucine on THP-1 cell cycle distribution was detected by PI single staining. RT-PCR was used to detect the expression of BCL-2 and BAX. The results showed that the brucine could inhibit the THP-1 cell growth in concentration and time-dependent manners at the range of 50 to 400 µg/ml. The cells stained with AO/EB revealed that the brucine induced the nuclear chromatin condensation. After the THP-1 cells were treated with brucine of 400µg/ml for 48 hours, most nucleic were stained as orange-red, and condensed, displaying the late apoptotic cell morphology. Annexin-V/PI detection showed that brucine could induce apoptosis of THP-1 cells in a concentration-dependent manner. Compared with the control group, more cells in brucine-treated group were arrested at G0/G1 phase in a concentration-dependent manner. RT-PCR detection revealed that the expression of BCL-2 was down-regulated strikingly and BAX was up-regulated. It is concluded that brucine can efficiently inhibit cell growth and block THP-1 cells in G0/G1 phase. The mechanism of THP-1 cell apoptosis induced by brucine may be related to the inhibition of BCL-2 and activation of BAX.

[A protein array based on quantum dots (QDs) encoded microbeads for detection of hepatitis C virus].

OBJECTIVE: To establish a hepatitis C virus (HCV) diagnostic assay using a protein array based on the quantum dots (QDs) encoded microbeads. METHOD: Using QDs encoded microbeads array and immunofluorescence techniques, the highly purified HCV NS3, NS4, NS5 and Core protein were respectively immobilized on the surface of encoded beads, which were used for the detection of anti-HCV antibody in serum. To evaluate the microbeads protein array, 120 HCV positive and 50 HCV negative samples were tested, and compared with recombinant immunoblot assay(RIBA) results as golden standard. The sensitivity, specificity and accuracy value were calculated. RESULTS: Compared 120 positive samples detected with RIBA, the sensitivity of microbeads array is 97.50% (117/120), the specificity is 96.0% (48/50), and accuracy is 97. 06% [(117 + 48)/(120 + 50)], The sensitivity of microbeads protein array is similar with RIBA methods. In the 120 positive samples tested with protein array, the positive rate of anti-HCV Core is 92. 50% (111/120) , the positive rate of anti-HCV NS3 is 89. 17% (107/120), the positive rate of anti-HCV NS4 is 70. 83% (85/120), the positive rate of anti-HCV NS5 is 52.50% (63/120).

pH-responsive controlled-release fertilizer with water retention via atom transfer radical polymerization of acrylic acid on mussel-inspired initiator.

This work reports a polydopamine-graft-poly(acrylic acid) (Pdop-g-PAA)-coated controlled-release multi-element compound fertilizer with water-retention function by a combination of mussel-inspired chemistry and surface-initiated atom transfer radical polymerization (SI-ATRP) techniques for the first time. The morphology and composition of the products were characterized by transmission electron microscopy (TEM), Fourier transform infrared (FTIR) spectroscopy, thermogravimetric analysis (TGA), gel permeation chromatography (GPC), and inductively coupled plasma (ICP) emission spectrometry. The results revealed that the stimuli-responsive layer formed by a Pdop inner layer and a PAA outer corona exhibit outstanding selective permeability to charged nutrients and the release rate of encapsulated elements can be tailored by the pH values. At low pH, the Pdop-g-PAA layer can reduce nutrient loss, and at high pH, the coating restrains transportation of negative nutrients but favors the release of cations. Moreover, PAA brushes provide good water-retention property. This Pdop-graft-polymer brushes coating will be effective and promising in the research and development of multi-functional controlled-release fertilizer.

Polydopamine film coated controlled-release multielement compound fertilizer based on mussel-inspired chemistry.

This work reports on a facile and reliable method to prepare a polydopamine film coated controlled-release multielement compound fertilizer (PCMCF) based on mussel-inspired chemistry for the first time. The polydopamine (Pdop) film was coated on double copper potassium pyrophosphate trihydrate, providing three essential nutrients (Cu, K, and P) by spontaneous oxidative polymerization of dopamine. The thickness of the polymer coating of the fertilizer was controlled by using the multistep deposition technique. The morphology and composition of the products were characterized by transmission electron microscopy, inductively coupled plasma emission spectrometer, a vis spectrophotometer, and a Kjeltec autoanalyzer. The controlled-release behavior of four elements, including nitrogen from Pdop, was evaluated in water and in soil (sterilized or not). The results revealed that the coated fertilizers had good slow-release properties, incubated in either water or soil. It is noted that the release rate of nutrients of PCMCF can be tailored by the thickness of the Pdop coating, and the Pdop coating can be biodegraded in soil. This coating technology will be effective and promising in the research and development of controlled-release fertilizer.

[Apoptosis-inducing effects of brucine on human chronic myeloid leukemia cell line K562].

To investigate the apoptosis-induction effect of brucine on human chronic myeloid leukemia cell line K562 cells, K562 cells were exposed to various dosages of brucine. MTT method was used to assayed the growth inhibition effect of brucine on K562 cells. The apoptosis of K562 cells was detected by acridine orange/ethidium bromide (AO/EB) double staining, Annexin-V/PI double labeling method and DNA agarose gel electrophoresis. The results showed that brucine could remarkably inhibit the K562 cell growth in a concentration-dependent and time-dependent manners at the range of 50 to 400 µg/ml, and its most significant inhibition was observed at 400 µg/ml for 72 hours and the inhibition rate was 94.0%. Staining of cells with AO-EB revealed that brucine induced nuclear chromatin condensation. After the K562 cells were treated with the brucine of 400 µg/ml for 72 hours, the most of the nucleus were orange stained and condensation-like or bead-like showing apoptotic morphology. The K562 cells treated with brucine of different concentrations (50, 100, 200, 400, 800 µg/ml) for 72 hours, Annexin-V/PI detection showed brucine could induce apoptosis of K562 cells, and apoptosis rate increased gradually with increasing concentration of drugs. The K562 cells treated with brucine of 400 µg/ml for 72 hours displayed typical ladder strap in DNA gel electrophoresis. It is concluded that brucine can efficiently inhibit cell growth and induce apoptosis of K562 cells with dose-dependent manner in concentrations of 50 - 400 µg/ml.

[Effect of brucine on secretion function and proliferation capability of T lymphocytes in patients with aplastic anemia].

The aim of this study was to investigate the effect of brucine on secretion of TNF-α, IFN-γ, IL-4 and proliferation of T lymphocytes in patients with aplastic anemia (AA), and to explore its mechanism. Peripheral blood T lymphocytes from 10 patients with AA and 10 healthy volunteers were isolated, purified and cultured. T lymphocytes from the patients were divided into 0, 100, 200 and 400 µg/ml brucine-treated groups. T lymphocytes from healthy volunteers were used as control group. After being cultured for 72 hours, the levels of TNF-α, IFN-γ, IL-4 in the supernatant of cultured T lymphocytes from AA patients were detected by ELISA, and the proliferation of T lymphocytes from AA patients was detected by MTT. The results showed that compared with the normal control group, the levels of TNF-α and IFN-γ in the culture supernatant significantly increased, and IL-4 was significantly decreased. The levels of TNF-α and IFN-γ in the culture supernatant of brucine treated groups were lower, and were dependent on the concentration of brucine. However, the levels of IL-4 were found to be not obviously changed. The inhibition rate of T lymphocytes in 100, 200 and 400µg/ml brucine-treated groups were (13.61 ± 4.31)%, (14.28 ± 4.31)% and (15.12 ± 4.56)% respectively, among which the differences were not statistically significant. It is concluded that the brucine can reduce the levels of TNF-α and IFN-γ through inhibiting the proliferation of T lymphocytes in AA patients, which provides experimental basis for therapy of AA patients.

{6,6'-Dimeth-oxy-2,2'-[ethane-1,2-diylbis(nitrilo-methyl-idyne)]diphenolato-1κO,O,O,O:2κO,N,N',O}(ethanol-1κO)-µ-nitrato-1:2κO:O'-dinitrato-1κO,O'-samarium(III)zinc(II).

In the title heteronuclear Zn(II)-Sm(III) complex, [SmZn(C(18)H(18)N(2)O(4))(NO(3))(3)(CH(3)CH(2)OH)], with the hexa-dentate Schiff base compartmental ligand N,N'-bis-(3-methoxy-salicyl-idene)ethyl-enediamine (H(2)L), the Sm(III) and Zn(II) ions are triply bridged by two phenolate O atoms from the Schiff base ligand and one nitrate anion. The five-coordinate Zn(II) ion is in a square-pyramidal geometry formed by the donor centers of two imine N atoms, two phenolate O atoms and one of the bridging nitrate O atoms. The Sm(III) center is in a ten-fold coordination of O atoms, involving the phenolate O atoms, two meth-oxy O atoms, one ethanol O atom, and two O atoms from two nitrate anions and one from the bridging nitrate anion. In the crystal, inter-molecular O-H⋯O and C-H⋯O inter-actions generate a layer structure extending parallel to (101).